Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dysplastic Nevus Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Dysplastic Nevus Syndrome. Displaying page 1 of 1.
    EudraCT Number: 2007-000427-17 Sponsor Protocol Number: CY503C1 Start Date*: 2007-10-26
    Sponsor Name:CYTAVIS BioPharma GmbH
    Full Title: A phase II multicenter study to test progression- free and overall survival of CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after antineoplastic treatment failure
    Medical condition: unresectable progressive metastatic melanoma stage IV after antineoplastic treatmet failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027152 Melanoma of skin (malignant) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003531-30 Sponsor Protocol Number: WIDECT Start Date*: 2020-04-03
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Electrochemotherapy versus narrow excision margins for high-risk, primary cutaneous melanoma
    Medical condition: primary cutaneous melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027155 Melanoma skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002276-13 Sponsor Protocol Number: CA209-7DL Start Date*: 2020-04-27
    Sponsor Name:University Hospital Essen, Department of Dermatology
    Full Title: Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification
    Medical condition: Stage II melanoma arising from a primary cutaneous site after surgery therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10025655 Malignant melanoma of skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006344-19 Sponsor Protocol Number: D1532C00006 Start Date*: 2009-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation ...
    Medical condition: BRAF mutation positive advanced cutaneous and unknown primary melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025654 Malignant melanoma of sites other than skin LLT
    9.1 10025670 Malignant melanoma stage III LLT
    9.1 10025671 Malignant melanoma stage IV LLT
    9.1 10027152 Melanoma of skin (malignant) LLT
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003921-51 Sponsor Protocol Number: BOT112-03 Start Date*: 2021-02-11
    Sponsor Name:Highlight Therapeutics
    Full Title: Phase 2 single arm clinical study to evaluate the efficacy and safety of intratumoral administration of BO-112 in combination with pembrolizumab in subjects that have progressed on anti-PD-1-based ...
    Medical condition: Advanced melanoma after progression to immunotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027155 Melanoma skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003729-41 Sponsor Protocol Number: CA209-915 Start Date*: Information not available in EudraCT
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma.
    Medical condition: Stage IIIb/c/d or Stage IV no evidence of disease (NED) melanoma following complete resection of the lesion(s) with high risk of relapse.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10040891 Skin melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) BE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Prematurely Ended) FR (Completed) GR (Completed) IT (Prematurely Ended) Outside EU/EEA RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002669-37 Sponsor Protocol Number: EMR200066-007 Start Date*: 2013-02-20
    Sponsor Name:Merck Serono S.A. Geneva
    Full Title: A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cuta...
    Medical condition: N-RAS mutated locally advanced or metastatic malignant cutaneous melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10025655 Malignant melanoma of skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003446-16 Sponsor Protocol Number: ATX-ME-001 Start Date*: 2022-07-27
    Sponsor Name:Achilles Therapeutics UK Limited
    Full Title: An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with metastatic or recurrent melanoma.
    Medical condition: Metastatic or recurrent melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072454 Amelanotic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072452 Angiotropic melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072447 Blue naevus-like melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072453 Blue nevus-like melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072449 Desmoplastic melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 100000004865 10025651 Malignant melanoma excision LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063706 Malignant melanoma of eyelid PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025653 Malignant melanoma of other specified sites of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025656 Malignant melanoma of skin of ear and external auditory canal LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025657 Malignant melanoma of skin of ear and external auricular canal LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056767 Malignant melanoma of skin of eyelid, incl canthus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025658 Malignant melanoma of skin of eyelid, including canthus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025659 Malignant melanoma of skin of lip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056768 Malignant melanoma of skin of lower limb, incl hip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025660 Malignant melanoma of skin of lower limb, including hip LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025661 Malignant melanoma of skin of other and unspecified parts of face LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025662 Malignant melanoma of skin of scalp and neck LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025663 Malignant melanoma of skin of trunk, except scrotum LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056792 Malignant melanoma of skin of trunk, excl scrotum LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056769 Malignant melanoma of skin of upper limb, incl shoulder LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025664 Malignant melanoma of skin of upper limb, including shoulder LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027149 Melanoma limited to extremity LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048434 Melanoma malignant aggravated LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027153 Melanoma of skin, site unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027154 Melanoma of trunk and head LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027155 Melanoma skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079054 Naevoid melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079068 Nevoid melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029488 Nodular melanoma PT
    20.0 100000004865 10074800 Skin malignant melanoma excision LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042547 Superficial spreading melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042551 Superficial spreading melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042552 Superficial spreading melanoma stage IV PT
    21.1 100000004865 10047981 Wide excision of melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018638-29 Sponsor Protocol Number: LUC10-001 Start Date*: 2012-04-23
    Sponsor Name:Centre du Cancer des Cliniques Universitaires Saint-Luc
    Full Title: Phase I/II study of peptide vaccination associated with GM-CT-01, a galactomannan oligomer that inhibits galestin-3, in patients with advanced metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10025651 Malignant melanoma excision LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042550 Superficial spreading melanoma stage II PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029488 Nodular melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025662 Malignant melanoma of skin of scalp and neck LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056768 Malignant melanoma of skin of lower limb, incl hip LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048434 Melanoma malignant aggravated LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042548 Superficial spreading melanoma in situ LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025652 Malignant melanoma in situ PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056792 Malignant melanoma of skin of trunk, excl scrotum LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025667 Malignant melanoma site/stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042553 Superficial spreading melanoma stage unspecified PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025660 Malignant melanoma of skin of lower limb, including hip LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025653 Malignant melanoma of other specified sites of skin LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024226 Lentigo melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025659 Malignant melanoma of skin of lip LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025665 Malignant melanoma of skin stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025661 Malignant melanoma of skin of other and unspecified parts of face LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056769 Malignant melanoma of skin of upper limb, incl shoulder LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042547 Superficial spreading melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025657 Malignant melanoma of skin of ear and external auricular canal LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027155 Melanoma skin LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025668 Malignant melanoma stage I PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027148 Melanoma in situ LLT
    14.0 10042613 - Surgical and medical procedures 10047981 Wide excision of melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025663 Malignant melanoma of skin of trunk, except scrotum LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025656 Malignant melanoma of skin of ear and external auditory canal LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027154 Melanoma of trunk and head LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042549 Superficial spreading melanoma stage I PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042552 Superficial spreading melanoma stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027149 Melanoma limited to extremity LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025664 Malignant melanoma of skin of upper limb, including shoulder LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025669 Malignant melanoma stage II PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027153 Melanoma of skin, site unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042551 Superficial spreading melanoma stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027156 Skin melanomas (excl ocular) HLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056767 Malignant melanoma of skin of eyelid, incl canthus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005569-10 Sponsor Protocol Number: Bottom_2012 Start Date*: 2013-08-19
    Sponsor Name:University Hospital Essen
    Full Title: Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastati...
    Medical condition: Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic), and determined to be BRAF V600 mutation-positive
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001937-40 Sponsor Protocol Number: EORTC 16032-18031 Start Date*: 2005-05-19
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma
    Medical condition: Unresectable and progressive metastatic cutaneous melanoma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027155 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003640-24 Sponsor Protocol Number: C4221023 Start Date*: 2023-01-16
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED...
    Medical condition: metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048434 Melanoma malignant aggravated LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027155 Melanoma skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025658 Malignant melanoma of skin of eyelid, including canthus LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025661 Malignant melanoma of skin of other and unspecified parts of face LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025663 Malignant melanoma of skin of trunk, except scrotum LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025660 Malignant melanoma of skin of lower limb, including hip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025659 Malignant melanoma of skin of lip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025656 Malignant melanoma of skin of ear and external auditory canal LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025662 Malignant melanoma of skin of scalp and neck LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025664 Malignant melanoma of skin of upper limb, including shoulder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025653 Malignant melanoma of other specified sites of skin LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027153 Melanoma of skin, site unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025657 Malignant melanoma of skin of ear and external auricular canal LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027154 Melanoma of trunk and head LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025666 Malignant melanoma of the anus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056768 Malignant melanoma of skin of lower limb, incl hip LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056767 Malignant melanoma of skin of eyelid, incl canthus LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056769 Malignant melanoma of skin of upper limb, incl shoulder LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056792 Malignant melanoma of skin of trunk, excl scrotum LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077160 Central nervous system melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Ongoing) DE (Ongoing) PL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001722-21 Sponsor Protocol Number: D533AC00001 Start Date*: 2022-03-08
    Sponsor Name:AstraZeneca AB
    Full Title: MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance ...
    Medical condition: Unresectable or Advanced Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing) PL (Ongoing) ES (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002073-22 Sponsor Protocol Number: 11_DOG12_56 Start Date*: 2015-07-28
    Sponsor Name:The Christie NHS Foundation Trust, R&D
    Full Title: A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma( PIANO)
    Medical condition: In a subset of patients with advanced acral and mucosal melanoma exhibiting Tyrosine Kinase Receptor gene(c-KIT) mutation.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027152 Melanoma of skin (malignant) LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000589 Acral lentiginous melanoma stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025667 Malignant melanoma site/stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000583 Acral lentiginous melanoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004046-16 Sponsor Protocol Number: IMC-F106C-101 Start Date*: 2020-04-08
    Sponsor Name:Immunocore Ltd.
    Full Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Pos...
    Medical condition: HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers. Study IMC-F106C-101 will enroll participants with advanced cancers, including unresectable or metastatic melanoma, ovarian ca...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025665 Malignant melanoma of skin stage unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046769 Uterine carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001050-33 Sponsor Protocol Number: 4SC-202-2-2017 Start Date*: 2017-08-21
    Sponsor Name:4SC AG
    Full Title: An open-label Phase Ib/ II, multi-center study of 4SC-202 in Combination with Pembrolizumab in Patients with Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma primary refractory/non-res...
    Medical condition: Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003555-38 Sponsor Protocol Number: CP-MGC018-01 Start Date*: 2019-08-05
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Sol...
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040891 Skin melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006711-29 Sponsor Protocol Number: ANV419-101 Start Date*: 2022-08-18
    Sponsor Name:Anaveon AG
    Full Title: A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti PD-1 or Anti-CTLA-4 Antibody Following Anti PD 1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cut...
    Medical condition: Unresectable or Metastatic Cutaneous Melanoma with prior Anti PD 1/Anti-PD-L1 Antibody Treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002971-12 Sponsor Protocol Number: IMCgp100-201 Start Date*: 2016-05-26
    Sponsor Name:Immunocore Limited
    Full Title: A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compa...
    Medical condition: Advanced Malignant Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA